PGE2 promotes renal carcinoma cell invasion through activated RalA

Cancer statistics, 2011

(2011) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Biased Ligands for Better Cardiovascular Drugs

(2011) Scott M. DeWire et al.   CIRCULATION RESEARCH

Aberrant PGE2 metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells

(2011) Evgeniy Eruslanov et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Prostaglandin E2Regulates Renal Cell Carcinoma Invasion through the EP4 Receptor-Rap GTPase Signal Transduction Pathway

(2011) Juanjuan Wu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Prognostic factors for survival in metastatic renal cell carcinoma

(2010) Ronald M. Bukowski   CANCER

Distinct Biological Roles for the Akt Family in Mammary Tumor Progression: Figure 1.

(2010) Rachelle L. Dillon et al.   CANCER RESEARCH

Immunity, Inflammation, and Cancer

(2010) Sergei I. Grivennikov et al.   CELL

Cancer and Inflammation: Implications for Pharmacology and Therapeutics

(2010) F Balkwill et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Ral GAP complex links PI 3-kinase/Akt signaling to RalA activation in insulin action

(2010) Xiao-Wei Chen et al.   MOLECULAR BIOLOGY OF THE CELL

Treatment of metastatic renal cell carcinoma

(2010) Maxine Sun et al.   Nature Reviews Urology

Immunotherapeutic strategies in kidney cancer—when TKIs are not enough

(2009) Swethajit Biswas et al.   Nature Reviews Clinical Oncology

Metastatic renal cell carcinoma: Results of a population-based study with 25 years follow-up

(2008) Anne Schlesinger-Raab et al.   EUROPEAN JOURNAL OF CANCER

The Ral GTPase pathway in metastatic bladder cancer: Key mediator and therapeutic target

(2008) Steven Christopher Smith et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Physiological Regulation of Prostaglandins in the Kidney

(2007) Chuan-Ming Hao et al.   Annual Review of Physiology